YIPF3 Inhibitors
Chemical inhibitors of YIPF3 can affect its function in various ways by targeting different aspects of cellular mechanisms. Brefeldin A, for example, inhibits protein transport by blocking ADP-ribosylation factors, leading to a disruption in vesicle formation and trafficking within the Golgi apparatus, which is integral to YIPF3's role. Similarly, Golgicide A specifically inhibits Golgi BFA resistance factor 1, impairing the formation and maintenance of the Golgi structure necessary for YIPF3's operations. Tunicamycin's inhibition of N-linked glycosylation interferes with the maturation of proteins that YIPF3 is involved with, while Monensin disrupts the ion gradients across the Golgi membrane, affecting the pH and ionic environment crucial for YIPF3's proper functioning. Nocodazole's interference with microtubule polymerization disrupts intracellular transport, inhibiting YIPF3's ability to properly deliver cargo proteins to and from the Golgi.
The actin cytoskeleton also plays a role in YIPF3's functional domain; Swinholide A and Jasplakinolide disrupt this structure by severing actin filaments and stabilizing them into aggregates, respectively, altering vesicle transport and morphology of the Golgi, where YIPF3 operates. Dynasore, inhibiting the GTPase activity of dynamin, affects vesicle scission in endocytosis and some Golgi trafficking pathways, which can disrupt the recycling pathways and transport to the Golgi, thereby inhibiting YIPF3. Exo1, by inhibiting the exocyst complex, affects the final stages of vesicular trafficking, impacting YIPF3's role in protein sorting and secretion. Furthermore, Salubrinal's blocking of eukaryotic translation initiation factor 2 alpha dephosphorylation can indirectly inhibit YIPF3 by disrupting overall protein trafficking and processing. Lastly, SecinH3 disrupts ARF-mediated processes by inhibiting cytohesins, affecting vesicle formation and transport essential for YIPF3's function. Each of these chemical inhibitors, through their unique mechanisms, can disrupt the normal function of YIPF3 by altering the cellular environment and the processes that facilitate its role in protein trafficking.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
Brefeldin A inhibits protein transport by blocking the activation of ADP-ribosylation factors (ARFs), crucial to vesicle formation and trafficking within the Golgi apparatus. Since YIPF3 is involved in the trafficking of proteins between the endoplasmic reticulum and the Golgi, inhibiting ARF would disrupt the proper functioning of YIPF3 by preventing the formation of transport carriers it would normally associate with. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $152.00 $515.00 | ||
Monensin acts as an ionophore that disrupts the ion gradients across the Golgi apparatus membrane, which affects the pH and ionic environment crucial for the functioning of Golgi-resident proteins like YIPF3. By altering the Golgi's internal environment, Monensin can inhibit the function of YIPF3 by preventing its proper folding and trafficking. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $169.00 $299.00 | 66 | |
Tunicamycin inhibits N-linked glycosylation by blocking the first step in the synthesis of the lipid-linked oligosaccharide precursor. YIPF3, being a Golgi-resident protein, is involved in protein processing, which includes glycosylation. Inhibition of this process can impair the function of YIPF3 by disrupting the maturation of proteins it is involved with. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $58.00 $83.00 $140.00 $242.00 | 38 | |
Nocodazole disrupts microtubule polymerization, which is essential for intracellular transport, including the trafficking between the endoplasmic reticulum and Golgi where YIPF3 operates. This disruption can inhibit the function of YIPF3 by preventing the proper delivery of cargo proteins to and from the Golgi. | ||||||
Golgicide A | 1005036-73-6 | sc-215103 sc-215103A | 5 mg 25 mg | $187.00 $670.00 | 11 | |
Golgicide A specifically inhibits Golgi BFA resistance factor 1 (GBF1), a GEF for ARF1, leading to Golgi disruption. This disruption can inhibit YIPF3 function by impairing the formation and maintenance of Golgi structure, which is necessary for YIPF3's role in protein trafficking. | ||||||
GM 6001 | 142880-36-2 | sc-203979 sc-203979A | 1 mg 5 mg | $75.00 $265.00 | 55 | |
Ilomastat is a broad-spectrum inhibitor of matrix metalloproteases (MMPs) that can affect the extracellular matrix (ECM) remodeling. Since ECM remodeling can influence intracellular trafficking pathways where YIPF3 is involved, ilomastat can indirectly inhibit YIPF3 function by modifying the external cues that dictate Golgi network dynamics. | ||||||
Exo1 | 461681-88-9 | sc-200752 sc-200752A | 10 mg 50 mg | $82.00 $291.00 | 4 | |
Exo1 is an exocyst complex inhibitor that can disrupt exocytosis. By inhibiting the exocyst complex, Exo1 can indirectly inhibit YIPF3 by preventing the final stages of vesicular trafficking in which YIPF3 might be involved, thereby affecting its functional role in protein sorting and secretion. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $87.00 | 44 | |
Dynasore inhibits the GTPase activity of dynamin, a crucial mediator of vesicle scission in endocytosis and some Golgi trafficking pathways. By inhibiting dynamin, Dynasore can disrupt the recycling pathways and transport to the Golgi, which can inhibit the function of YIPF3 in trafficking processes. | ||||||
Swinholide A, Theonella swinhoei | 95927-67-6 | sc-205914 | 10 µg | $135.00 | ||
Swinholide A disrupts actin cytoskeleton by severing actin filaments. The actin cytoskeleton is implicated in maintaining Golgi structure and trafficking, so its disruption can inhibit YIPF3's function by altering vesicle transport and Golgi morphology. | ||||||
Jasplakinolide | 102396-24-7 | sc-202191 sc-202191A | 50 µg 100 µg | $180.00 $299.00 | 59 | |
Jasplakinolide stabilizes actin filaments and can lead to the formation of actin aggregates. By affecting the dynamics of the actin cytoskeleton, it can disrupt the trafficking and sorting processes within the Golgi where YIPF3 functions, thus inhibiting its role in those processes. | ||||||